WO1994023716A1 - Method for treatment of menopausal and premenstrual symptoms - Google Patents
Method for treatment of menopausal and premenstrual symptoms Download PDFInfo
- Publication number
- WO1994023716A1 WO1994023716A1 PCT/US1994/004189 US9404189W WO9423716A1 WO 1994023716 A1 WO1994023716 A1 WO 1994023716A1 US 9404189 W US9404189 W US 9404189W WO 9423716 A1 WO9423716 A1 WO 9423716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dietary product
- isoflavonoid
- isoflavonoids
- daidzein
- genistein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Definitions
- the present invention relates to therapies for the prevention and treatment of menopausal and premenstrual symptoms.
- menopause symptoms, e.g., hot flashes, nausea, nervousness, and malaise.
- estrogen replacement therapy has recently been shown to increase the risk of certain types of cancer, such as endometrial cancer and breast cancer. Changes in levels of endogenous estrogen may also be responsible for "premenstrual syndrome", a condition occuring in younger women prior to menstruation.
- Premenstrual symptoms are treated with a variety of hormonal and nonhormonal therapies, which may cause side effects. Safer and more effective therapies for both conditions continue to be sought.
- isoflavonoids which are constituents of soy beans and other plants
- estrogen e.g., menopause
- premenstrual syndrome e.g., menopause
- Isoflavonoids bind to estrogen receptors, and thus exert an estrogenic response. These compounds, which are present naturally in soy-based and other plant-based foods, are safe and cause no significant side-effects.
- Isoflavonoids which may be administered according to the invention include genistein, daidzein, Biochanin A, formononetin, O-desmethylangolensin, and equol; these may be administered alone or in combination.
- the invention features a method of preventing or treating the symptoms of menopause, premenstrual syndrome, or a condition
- the isoflavonoid may be any suitable isoflavonoid.
- the isoflavonoid may be any suitable isoflavonoid.
- isoflavonoids administered in any suitable form, e.g., in the form of a plant extract rich in isoflavonoids or in the form of a purified or synthesized isoflavonoid.
- the invention features a therapeutic dietary product for preventing or treating symptoms resulting from reduced or altered levels of endogenous estrogen.
- the dietary product preferably includes a soy extract containing enriched isoflavonoids, provided in a palatable food carrier, e.g., a
- Isoflavonoids are naturally occurring substances, found primarily in soy beans. These compounds are also found in lower concentrations in many other plants.
- Isoflavonoids can thus be administered to a patient by placing the patient on a diet containing high levels of soy-based food products, e.g., tofu, miso, soybeans, aburage, atuage and koridofu, or other plant products rich in isoflavonoids.
- soy-based food products e.g., tofu, miso, soybeans, aburage, atuage and koridofu, or other plant products rich in isoflavonoids.
- an isoflavonoid-containing fraction can be extracted from a soy or plant product. It is preferred that the isoflavonoids be extracted and
- the concentrated isoflavonoids are also available commercially in substantially pure form.
- the concentrated isoflavonoid is preferably included in a food carrier to form a dietary product.
- Any type of palatable carrier may be used, but, as the isoflavonoid concentrate has a strong flavor, it is preferred that the carrier include suitable flavorings to impart a different, more palatable flavor.
- the dietary product may be any type of food product, e.g., a
- the dietary product contain at least 30 mg/serving total isoflavonoids.
- isoflavonoid concentrate included in the dietary product preferably includes a blend primarily comprised of genistein and daidzein.
- the concentrate typically also contains lower levels of other isoflavonoids.
- the dietary product contains from about 10 to 30 mg/serving, more preferably about 20 mg/serving of genistein, and from about 5 to 10 mg/serving, more preferably about 7 mg/serving of daidzein.
- a dietary product containing the preferred dosage of isoflavonoids would be consumed at least once per day, preferably l to 2 times per day depending upon the severity of the woman's symptoms.
- the isoflavonoid be administered in the form of a dietary product
- the isoflavonoid could be administered, preferably in similar dosages, in medicament form, e.g., mixed with a pharmaceutically acceptable carrier to form a tablet, powder or syrup.
- Isoflavonoid excretion in the urine was measured in a group of three men, three women, and three children living in Kyoto and consuming the traditional diet. We found a very high excretion of isoflavonoids in the urine of these subjects. The mean values were almost identical in the two groups and especially high excretion was found for genistein (maximum 15.5 umol per 24h in a man) and two other isoflavonoids, daidzein and equol (Table 1). All these compounds bind to estrogen receptors and have weak estrogenic activity. The excretion of the
- isoflavonoids in urine of the Japanese women was much higher than previously determined levels in American and Finnish women (Table l) .
- Excretion was high in children as in middle-aged and old people. These compounds were excreted in 100-fold to 1000-fold higher amounts than the levels of endogenous estrogens excreted by normal
- the excretion of the isoflavonoids in urine was associated with intake of soy products such as tofu, miso, aburage, atuage, koridofu, soybeans, and boiled beans.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94914194A EP0693927A4 (en) | 1993-04-16 | 1994-04-15 | Method for treatment of menopausal and premenstrual symptoms |
AU66359/94A AU6635994A (en) | 1993-04-16 | 1994-04-15 | Method for treatment of menopausal and premenstrual symptoms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4900693A | 1993-04-16 | 1993-04-16 | |
US08/049,006 | 1993-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994023716A1 true WO1994023716A1 (en) | 1994-10-27 |
Family
ID=21957593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/004189 WO1994023716A1 (en) | 1993-04-16 | 1994-04-15 | Method for treatment of menopausal and premenstrual symptoms |
Country Status (5)
Country | Link |
---|---|
US (1) | US5498631B1 (en) |
EP (1) | EP0693927A4 (en) |
AU (1) | AU6635994A (en) |
CA (1) | CA2160371A1 (en) |
WO (1) | WO1994023716A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656786A1 (en) | 1992-05-19 | 1995-06-14 | KELLY, Graham Edmund | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
WO1998050026A1 (en) * | 1997-05-01 | 1998-11-12 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
EP0903143A2 (en) * | 1997-09-19 | 1999-03-24 | Protein Technologies International, Inc. | Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels |
EP0934060A1 (en) * | 1996-07-30 | 1999-08-11 | Energetics, Inc. | Dietary supplements |
WO1999049862A1 (en) * | 1998-03-30 | 1999-10-07 | The University Of Mississippi | Isoflavones for treating giardiasis and malaria |
US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
EP0971695A1 (en) * | 1996-12-13 | 2000-01-19 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
EP0998262A4 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US6083526A (en) * | 1997-05-22 | 2000-07-04 | Gorbach; Sherwood L. | Use of isoflavonoids in the treatment or prevention of postpartum depression |
EP1025850A1 (en) * | 1997-08-08 | 2000-08-09 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing compositions |
US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
US6599536B1 (en) | 1998-03-26 | 2003-07-29 | Novogen Research Pty Ltd | Therapy of estrogen-associated disorders |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
AU779210B2 (en) * | 1997-05-01 | 2005-01-13 | Novogen Inc | Treatments or prevention of menopausal symptoms and osteoporosis |
EP1545206A2 (en) | 2002-07-24 | 2005-06-29 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
US7056952B1 (en) | 1999-04-30 | 2006-06-06 | G.J. Consultants Pty. Ltd. | Isoflavone metabolites |
AU2004224982B2 (en) * | 1996-08-30 | 2007-09-13 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
WO2008016768A1 (en) * | 2006-08-02 | 2008-02-07 | Roberta Diaz Brinton | Phytoestrogenic formulations and uses thereof |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
AU2007201805B2 (en) * | 1996-08-30 | 2009-03-26 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US8153684B2 (en) | 2002-10-29 | 2012-04-10 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US8552057B2 (en) | 2006-08-02 | 2013-10-08 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
US8680140B2 (en) | 2006-08-02 | 2014-03-25 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003084A1 (en) * | 1996-07-18 | 1998-01-29 | Nutricor, Inc. | Nutritious food preparations and methods for making them |
US6040333A (en) * | 1996-07-30 | 2000-03-21 | Energetics, Inc. | Dietary supplements |
WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
AU5260798A (en) * | 1996-11-18 | 1998-06-10 | Internutria, Inc. | Compositions and treatment for nighttime persistent reproductive transition symptoms |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
DE69916414T2 (en) | 1998-07-16 | 2005-05-19 | Aaron Tabor | SOY PREPARATIONS AND THEIR USE IN HEALTH PROMOTION |
AU767245B2 (en) | 1998-11-25 | 2003-11-06 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
WO2000030664A1 (en) | 1998-11-25 | 2000-06-02 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
MXPA01008598A (en) * | 1999-02-24 | 2003-06-24 | Szabo Joseph | Dietary compositions and methods. |
US6174542B1 (en) | 1999-07-01 | 2001-01-16 | Pms Mood Food, Inc. | Dietary supplements and food products for treating symptoms of PMS |
US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
AUPQ520300A0 (en) * | 2000-01-21 | 2000-02-17 | Novogen Research Pty Ltd | Food product and process |
IL135335A (en) * | 2000-03-29 | 2013-12-31 | Lycored Natural Prod Ind Ltd | Use of carotenoids in the preparation of medicaments for preventing hormone induced adverse effects and pharmaceutical compositions comprising carotenoids |
DE60134702D1 (en) | 2000-08-16 | 2008-08-21 | Unilever Nv | Mixtures of isoflavones and flavones |
US6326366B1 (en) | 2000-08-22 | 2001-12-04 | Protein Technologies International | Hormone replacement therapy |
US20050119301A1 (en) * | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
WO2002085396A1 (en) * | 2001-04-24 | 2002-10-31 | President And Fellows Of Harvard College | Inhibition of jun kinase |
US7232897B2 (en) * | 2001-04-24 | 2007-06-19 | Harvard University, President And Fellows Of Harvard College | Compositions and methods for modulating NH2-terminal Jun Kinase activity |
US7025998B2 (en) | 2003-05-30 | 2006-04-11 | Rotta Research Laboratorium S.P.A. | Phytoestrogens and probiotic for women's health |
JP5220406B2 (en) * | 2004-04-28 | 2013-06-26 | ブリガム・ヤング・ユニバーシティ | Use of equol to treat skin diseases |
WO2007105147A1 (en) * | 2006-03-14 | 2007-09-20 | The Procter & Gamble Company | Absorbent articles with lotions |
TWI774660B (en) * | 2016-03-08 | 2022-08-21 | 日商大塚製藥股份有限公司 | Improving agent for physical and/or mental discomfort specific to female |
KR102542842B1 (en) | 2016-09-22 | 2023-06-14 | 알란 비. 캐쉬 | How to relieve the symptoms of PMS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864362A (en) * | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6048924A (en) * | 1983-08-24 | 1985-03-16 | Takeda Chem Ind Ltd | Remedy for osteoporosis |
IT1244697B (en) * | 1991-02-01 | 1994-08-08 | Chiesi Farma Spa | PHARMACEUTICAL ASSOCIATION FOR THE PREVENTION AND TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS |
NZ252051A (en) * | 1992-05-19 | 1996-10-28 | Graham Edmund Kelly | Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin |
-
1994
- 1994-04-15 CA CA002160371A patent/CA2160371A1/en not_active Abandoned
- 1994-04-15 EP EP94914194A patent/EP0693927A4/en not_active Withdrawn
- 1994-04-15 AU AU66359/94A patent/AU6635994A/en not_active Abandoned
- 1994-04-15 WO PCT/US1994/004189 patent/WO1994023716A1/en not_active Application Discontinuation
- 1994-08-01 US US08283678 patent/US5498631B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864362A (en) * | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642212B1 (en) | 1992-05-19 | 2003-11-04 | Novogen Research Pty. Ltd. | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
EP0656786A1 (en) | 1992-05-19 | 1995-06-14 | KELLY, Graham Edmund | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
EP0656786B2 (en) † | 1992-05-19 | 2014-04-23 | Novogen Research Pty Ltd | Use of isoflavone phyto-oestrogen extracts of soy or clover |
US6562380B1 (en) | 1992-05-19 | 2003-05-13 | Novogen Research Pty Limited | Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen |
US6497906B1 (en) | 1992-05-19 | 2002-12-24 | Novogen Research Pty. Ltd. | Dietary supplements comprising soy hypocotyls containing at least one isoflavone |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
EP0934060A4 (en) * | 1996-07-30 | 2001-01-03 | Energetics | Dietary supplements |
EP0934060A1 (en) * | 1996-07-30 | 1999-08-11 | Energetics, Inc. | Dietary supplements |
AU2004224982B2 (en) * | 1996-08-30 | 2007-09-13 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP1927352A2 (en) * | 1996-08-30 | 2008-06-04 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
EP1927352A3 (en) * | 1996-08-30 | 2008-11-19 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
GB2331015A (en) * | 1996-08-30 | 1999-05-12 | Novogen Res Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP0954302A4 (en) * | 1996-08-30 | 2005-03-02 | Novogen Res Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP0954302A1 (en) * | 1996-08-30 | 1999-11-10 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
US6649648B1 (en) | 1996-08-30 | 2003-11-18 | Novogen Research Pty Limited | Therapeutic methods and compositions involving isoflavones |
JP2009102342A (en) * | 1996-08-30 | 2009-05-14 | Novogen Research Pty Ltd | Therapeutic method and composition involving isoflavones |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
AU2007201805B2 (en) * | 1996-08-30 | 2009-03-26 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
GB2331015B (en) * | 1996-08-30 | 2001-05-09 | Novogen Res Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP0971695A4 (en) * | 1996-12-13 | 2002-08-07 | Sherwood L Gorbach | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
EP0971695A1 (en) * | 1996-12-13 | 2000-01-19 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
WO1998050026A1 (en) * | 1997-05-01 | 1998-11-12 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
AU779210B2 (en) * | 1997-05-01 | 2005-01-13 | Novogen Inc | Treatments or prevention of menopausal symptoms and osteoporosis |
US6340703B1 (en) | 1997-05-01 | 2002-01-22 | Novogen, Inc. | Treatment or prevention of osteoporosis |
US6083526A (en) * | 1997-05-22 | 2000-07-04 | Gorbach; Sherwood L. | Use of isoflavonoids in the treatment or prevention of postpartum depression |
EP0998262A1 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
EP0998262A4 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
EP1656942A2 (en) * | 1997-08-08 | 2006-05-17 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing composition |
EP1656942A3 (en) * | 1997-08-08 | 2008-02-27 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing composition |
US7939060B2 (en) | 1997-08-08 | 2011-05-10 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing composition |
US6716424B1 (en) | 1997-08-08 | 2004-04-06 | Otsuka Pharmaceutical Co., Ltd. | Streptococcus and isoflavone-containing composition |
EP1025850A1 (en) * | 1997-08-08 | 2000-08-09 | Otsuka Pharmaceutical Co., Ltd. | Isoflavone-containing compositions |
US7345089B2 (en) | 1997-08-08 | 2008-03-18 | Otsuka Pharmaceutical Co., Ltd. | Microbial method of making equol-containing composition and product made |
EP1025850A4 (en) * | 1997-08-08 | 2002-08-14 | Otsuka Pharma Co Ltd | Isoflavone-containing compositions |
EP0903143A3 (en) * | 1997-09-19 | 1999-05-06 | Protein Technologies International, Inc. | Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels |
EP0903143A2 (en) * | 1997-09-19 | 1999-03-24 | Protein Technologies International, Inc. | Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels |
US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
US6599536B1 (en) | 1998-03-26 | 2003-07-29 | Novogen Research Pty Ltd | Therapy of estrogen-associated disorders |
WO1999049862A1 (en) * | 1998-03-30 | 1999-10-07 | The University Of Mississippi | Isoflavones for treating giardiasis and malaria |
US7056952B1 (en) | 1999-04-30 | 2006-06-06 | G.J. Consultants Pty. Ltd. | Isoflavone metabolites |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
EP1545206A2 (en) | 2002-07-24 | 2005-06-29 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
US7960432B2 (en) | 2002-07-24 | 2011-06-14 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US8048913B2 (en) | 2002-07-24 | 2011-11-01 | Australian Health & Nutrition Assoc. Ltd. | Compositions and products containing S-equol, and methods for their making |
EP1545206B1 (en) * | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
US9408824B2 (en) | 2002-07-24 | 2016-08-09 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US9173866B2 (en) | 2002-07-24 | 2015-11-03 | Children's Hospital Medical Center | Compositions and products containing R-equol, and methods for their making |
US9018247B2 (en) | 2002-07-24 | 2015-04-28 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
US7468445B2 (en) | 2002-08-07 | 2008-12-23 | University Of Mississippi | Antigiardial agents and use thereof |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
US8450364B2 (en) | 2002-10-29 | 2013-05-28 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US9089547B2 (en) | 2002-10-29 | 2015-07-28 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US9408825B2 (en) | 2002-10-29 | 2016-08-09 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US9889116B2 (en) | 2002-10-29 | 2018-02-13 | Bringham Young University | Use of equol for treating androgen mediated diseases |
US10111855B2 (en) | 2002-10-29 | 2018-10-30 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US8153684B2 (en) | 2002-10-29 | 2012-04-10 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US8680140B2 (en) | 2006-08-02 | 2014-03-25 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms |
US8552057B2 (en) | 2006-08-02 | 2013-10-08 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases |
WO2008016768A1 (en) * | 2006-08-02 | 2008-02-07 | Roberta Diaz Brinton | Phytoestrogenic formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2160371A1 (en) | 1994-10-27 |
AU6635994A (en) | 1994-11-08 |
EP0693927A1 (en) | 1996-01-31 |
US5498631A (en) | 1996-03-12 |
US5498631B1 (en) | 1998-03-03 |
EP0693927A4 (en) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5498631A (en) | Method for treatment of menopausal and premenstrual symptoms | |
CA2287965C (en) | Treatment or prevention of menopausal symptoms and osteoporosis | |
US6900240B2 (en) | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer | |
EP0656786B1 (en) | Use of isoflavone phyto-oestrogen extracts of soy or clover | |
AU724813B2 (en) | Isoflavonoids for treatment and prevention of Alzheimer dementia and reduced cognitive functions | |
US20020187211A1 (en) | Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions | |
WO1998052546A1 (en) | Use of isoflavonoids in the treatment or prevention of postpartum depression | |
WO1999061028A1 (en) | Isoflavonoids for treatment and prevention of migraine headaches | |
Anderson | Phytoestrogen effects in humans relative to risk for cardiovascular disease, breast cancer, osteoporosis, and menopausal symptoms | |
JP2000157207A (en) | Functional food | |
AU779210B2 (en) | Treatments or prevention of menopausal symptoms and osteoporosis | |
AU777632B2 (en) | Health supplements containing isoflavones | |
AU7017198A (en) | Treatment or prevention of menopausal symptoms and osteoporosis | |
Baker | Phytoestrogens for menopausal women | |
TW200403986A (en) | A composition including isoflavones refined from plant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994914194 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2160371 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994914194 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994914194 Country of ref document: EP |